Hjem
Universitetet i Bergen
Mohn kreftforskningslaboratorium

Varselmelding

There has not been added a translated version of this content. You can either try searching or go to the "area" home page to see if you can find the information there
Study using PARP-inhibitors

Targeted therapy

Bergens Tidende shares the story of Aud and Kristel on 5 November; two ladies who have both been treated for breast cancer.

Articel print screen Bergens Tidende
Foto/ill.:
Print screen, Bergens Tidende 5 November 2020

Hovedinnhold

Publisert: 19.02.2021

Chief physician and researcher Hans Petter Eikesdal has been interviewed in Bergens Tidende about the study that Aud Pisani had the opportunity to participate in when she was diagnosed with breast cancer.

The included patients are treated with Parp inhibitors; a drug that disrupts and creates chaos in the cancer cells so that they die.

"-We see that there are more who have the effect of such a treatment. It is much more gentle than traditional chemotherapy" says Eikesdal to the newspaper. Read more about the study here.

The whole article can be read here.

Related content 
Protocol

Personalized therapy of breast cancer

Breast cancer therapy has improved significantly over the last decades. However, more than 3.700 Norwegian women are diagnosed with breast cancer (BC) and approximately 600 die from the disease annually, demonstrating that BC is a major health problem.